Navigation Links
SBRT provides better outcomes than surgery for cancer patients with common lung disease
Date:2/16/2012

Stereotactic body radiotherapy (SBRT) provides better overall survival rates than surgery for lung cancer patients with severe chronic obstructive pulmonary disease (COPD), a disease commonly associated with lung cancer, according to a study in the upcoming March issue of the International Journal of Radiation, Oncology, Biology, Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).

COPD is a blanket term for progressive lung diseases, including emphysema, chronic bronchitis and refractory asthma. It is characterized by increasing breathlessness and is present in 50 to 70 percent of lung cancer patients at the time of diagnosis. Patients with severe forms of this disease have a high annual mortality rate, even when they do not have lung cancer.

Surgery has been the standard treatment for Stage I non-small-cell lung cancer patients, but when the patient has COPD their chances of postoperative complications increase. SBRT, a newer radiation treatment, has been proven to be safe and effective in Stage I lung cancer patients who are not good surgical candidates.

Researchers looked at outcomes of post-SBRT Stage I lung cancer patients with severe COPD. The mean 30-day mortality rate post-SBRT was zero compared to 10 percent post-surgery. The overall survival rate post-SBRT was 79-95 percent at one year and 43-70 percent at three years. Post-surgery overall survival rates at one and three years were 45-86 percent and 31-66 percent, respectively.

"SBRT is a safe and effective less-invasive option for lung cancer patients with COPD that does not have the added risks of surgery-related mortality and prolonged hospitalization," David Palma, MD, MSc, lead author of the study and a radiation oncologist at the London Regional Cancer Program in London, Ontario, Canada, said. "All eligible patients should be evaluated in a multidisciplinary setting and afforded an informed decision of the risks and benefits of both surgery and SBRT."


'/>"/>
Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. New analysis provides clearer picture of cancer risks associated with Lynch syndrome
2. New data provides direction for ACL injured knee treatments
3. Orthopaedic surgery report provides transparency on patient safety, quality initiatives
4. Life and activity monitor provides portable, constant recording of vital signs
5. Radiation plus chemotherapy provides long-term positive results for head and neck cancer patients
6. Natural enzyme provides potential new approach for treating graft-vs.-host disease
7. New safe practices room provides prevention training space for nursing students
8. Research provides clues to neurodevelopemental disorders
9. AAP President provides update on agenda for children
10. TGen provides scientific launch pad for Helios Scholars
11. Evolution provides clue to blood clotting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology: